Premium
Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD)
Author(s) -
Blum Ronald H.,
Corson Joseph M.,
Wilson Richard E.,
Greenberger Joel S.,
Canellos George P.,
Frei Emil
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19801015)46:8<1722::aid-cncr2820460803>3.0.co;2-m
Subject(s) - medicine , cyclophosphamide , vincristine , sarcoma , chemotherapy , gastroenterology , dacarbazine , toxicity , oncology , surgery , pathology
Fifty consecutive adults with sarcoma were treated with Adriamycin (45 mg/m 2 ) on day 1, cyclophosphamide (500 mg/m 2 ) on day 2, and DTIC (400 mg/m 2 ) on days 1 and 2 (CAD). Of the 23 patients with measurable metastatic disease, 4 patients (17%) had a complete response, 9 patients (39%) had a partial response, 5 patients (22%) had stabilization, but 5 patients (22%) did not respond. The actuarial survival of complete and partial responders was 31.5 months compared to 5.5 months for non‐responders ( P < .005). Chemotherapy doses were escalated to a median lowest white count of 700 cells/mm 3 . Acute gastrointestinal toxicity and alopecia occurred in all patients. CAD differed from previously reported combinations by omission of vincristine, a two‐day dose schedule and dose rate intensification. CAD is recommended for patients with metastatic sarcoma.